Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States

References

• American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–s27.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.
   Google Scholar
• American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55–S64.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117.
   PubMed Web of Science ®Google Scholar
• Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–309.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE clinical guideline. Type 2 diabetes in adults: management. [updated 2015 Dec 02; cited 2018 July 16]. Available from: http://nice.org.uk/guidance/ng28.
   Google Scholar
• Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications?. J Diabetes Complications. 1995;9(1):25–30.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Fox KM, Gerber Pharmd RA, Bolinder B, et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28(3):388–395.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Wells BJ, Chagin KM, et al. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Dia Care. 2016;39(9):1527–1534.
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279.
   PubMed Web of Science ®Google Scholar
• Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28(3):600–606.
   PubMed Web of Science ®Google Scholar
• Wetzler HP, Snyder JW. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care. 2000;23(11):1637–1641.
   PubMed Web of Science ®Google Scholar
• Zafar A, Davies M, Azhar A, et al. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4(4):203–207.
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Ash AS, Glickman M, et al. Developing a quality measure for clinical inertia in diabetes care. Health Serv Res. 2005;40(6 Pt 1):1836–1853.
   PubMed Web of Science ®Google Scholar
• Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23(5):588–594.
   PubMed Web of Science ®Google Scholar
• Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, et al. A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. PLoS One. 2011;6(9):e24278.
   PubMed Web of Science ®Google Scholar
• Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31(4):564–571.
   PubMed Web of Science ®Google Scholar
• Fu AZ, Qiu Y, Davies MJ, et al. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab. 2011;13(8):765–769.
   PubMed Web of Science ®Google Scholar
• Crawford AG, Cote C, Couto J, et al. Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database. Popul Health Manag. 2010;13(3):151–161.
   PubMed Web of Science ®Google Scholar
• Crawford AG, Cote C, Couto J, et al. Comparison of GE centricity electronic medical record database and national ambulatory medical care survey findings on the prevalence of major conditions in the United States. Popul Health Manag. 2010;13(3):139–150.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, et al. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Cur Med Res Opin. 2013;29(11):1495–1502.
   PubMed Web of Science ®Google Scholar
• Yu S, Schwab P, Bian B, et al. Use of add-on treatment to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: A U.S. database study. J Manag Care Spec Pharm . 2016;22(3):272–280.
   PubMedGoogle Scholar
• Kartoun U, Iglay K, Shankar RR, et al. Factors associated with clinical inertia in type 2 diabetes mellitus patients treated with metformin monotherapy. Cur Med Res Opin. 2019;35(12):2063–2070.
   PubMed Web of Science ®Google Scholar